Day: November 6, 2024

HighlightsThe Hearing division continued to gain significant market share leading to 10% organic revenue growth, while the divisional profit margin increased by 5.9 percentage points to 34.8% The Enterprise division was negatively impacted by sell-in pressure due to economic growth challenges in parts of Central Europe, while North America and Rest of World continued its stabilization. Overall, organic revenue growth ended at -7%, while sell-out growth was -3%. Despite the topline development, the company-wide synergies led to a divisional profit margin of 33.8% The Gaming & Consumer division executed strongly on the wind-down of the Elite & Talk product lines, while SteelSeries was impacted by a slightly declining market, and some quarterly fluctuations including delays in certain order deliveries. The divisional profit margin...

PRESS INFORMATIONHeading: 3rd quarter 2024 revenues        Nanterre, November 6, 2024 (after trading) Organic growth up 10.5% in 3rd quarter 2024(not audited, in millions of euros) 2023 2024 growth of which organic3rd quarter revenues 177 196.7 + 11.1% + 10.5%Total as at the end-September 545.7 599.1 + 9.8% + 8.9%Achievements NEURONES posted double-digit organic growth in the 3rd quarter. The most notable advances continue to be in Data, Digital Projects, Cybersecurity, Sovereign and Secure Cloud (SecNumCloud). Total turnover is down 3 points (14.3% vs. 17.3% a year ago). Over the entire nine-month period, operating profit * amounted to 9.6% of revenues. Outlook For 2024, NEURONES confirms its forecasts made at the beginning of the year (around €800 million in revenues and 9.5% in operating profit). * not audited and after...

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 HighlightsEuropean Commission (EC) granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy Genmab announced that it will assume sole responsibility for the continued development and potential commercialization of acasunlimab Genmab revenue increased 29% compared to the first nine months of 2023, to DKK 15,085 million Genmab 2024 financial guidance updated“The third quarter of 2024 presented Genmab with additional opportunities to progress towards our goal of fundamentally transforming the lives of people with cancer and other serious diseases. The additional approval...

Heimar reports a profit of ISK 5.6 billion in the first nine months of the year – EBITDA rises by 7.5%  Key Highlights of the Nine-Month Results Operating revenue was ISK 10.9 billion in the first nine months, with rental income increasing by 7.8% year-over-year, slightly exceeding inflation by approximately 1.1%. EBITDA reached ISK 7.4 billion, marking a 7.5% increase compared to the same period in 2023. Profit totaled ISK 5.6 billion, up from ISK 5.1 billion in the previous year. Investment properties were valued at ISK 192.9 billion. Changes in investment property valuations amounted to ISK 7.6 billion for the first nine months. Cash from operations was ISK 4.4 billion, with cash on hand at ISK 4.1 billion at the period’s end. Interest-bearing debt stood at ISK 120.4 billion at the end of the period. ...

At a board meeting on 6 November 2024, the Board of Directors and the CEO approved the interim financial statements of Kvika banki hf. (“Kvika” or “the bank”) for the third quarter and first nine months of 2024. In Kvika’s financial statements for the period the insurance subsidiary TM tryggingar hf. (“TM”) is classified as held for sale. As a result, and in accordance with international financial reporting standards, the Group reports income from operations of TM in a single line in the consolidated income statement as profit after tax from discontinued operations. The comparative figures of operations from 2023 have been restated accordingly. Highlights of performance in the third quarter (Q3 2024)Profit before tax from continuing operations amounts to ISK 1,813 million, compared to ISK 234 million in Q3 2023, increasing by ISK 1,579...